Mobile

XERXES: Examining the role of early neoadjuvant and synchronous Erbitux in pre-operative chemo-radiotherapy using Xeloda followed by excisional surgery. A phase I/II dose escalation study of intrave...

Mise à jour : Il y a 4 ans
Référence : EUCTR2004-001926-26

XERXES: Examining the role of early neoadjuvant and synchronous Erbitux in pre-operative chemo-radiotherapy using Xeloda followed by excisional surgery. A phase I/II dose escalation study of intravenous erbitux (cetuximab) in combination with 5 day weekly oral Xeloda (capecitabine) and preoperative radiotherapy in rectal cancer

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate the safety and toxicity of the combination of erbitux, capecitabine and radiotherapy. This will be determined through an assessment of the patient’s toxicity

Critère d'inclusion

  • Locally advanced rectal cancer

Liens